Thank you, and welcome everybody to the reconvened special meeting of stockholders of NovaBay Pharmaceuticals. It is now 11:00 A.M. Pacific Time, and the meeting will please come to order. My name is Justin Hall, and as CEO and General Counsel and a director of NovaBay, I will preside over this reconvened meeting and serve as its chairman and secretary. I would like to introduce you to the other members of our board of directors and guests who are participating virtually today: Paul Freeman, chairman of the board and chair of the compensation committee. Also present with us today are Tommy Law, our interim chief financial officer; Bree Harrison, our senior director of business and sales operations; Catherine Weeden, a representative of Broadridge Financial Solutions who will serve as the inspector of election; and Abby Brown, a representative of Squire Patton Boggs, our outside counsel. This reconvened special meeting is a continuation of the special meeting of stockholders held on November 22nd. We adjourned the special meeting until today in order to provide for additional time to solicit stockholders to vote on Proposal One and Proposal Two, which did not receive sufficient number of votes for approval at the originally convened special meeting on November 22nd. Proposal One is the proposal to approve the sale of Avenova, representing substantially all of the assets of the company, pursuant to the Asset Purchase Agreement dated September 19th, 2024, by and between the company and PRN Physician Recommended Nutraceuticals, and Proposal Two is the proposal to approve the liquidation and dissolution of the company, pursuant to a plan of complete liquidation and dissolution, and pursuant to the discretion of the board of directors to proceed with the dissolution. Proposal One and Proposal Two are described and set forth in the company's proxy statement that were prepared for the special meeting as subsequently supplemented from time to time and was made available to stockholders in advance of this meeting. The board has approved Proposal One and Proposal Two. However, these proposals are also subject to the approval of our stockholders. We have an affidavit from Broadridge certifying that each stockholder of record, as of October 15th, 2024, the record date of this meeting, was mailed an official notice of the special meeting on or about October 16th, 2024. The affidavit is hereby accepted. Additionally, in connection with the adjournment of the special meeting, notice of the date, time, and place of this reconvened special meeting was provided to stockholders at the special meeting held on November 22nd, 2024, in accordance with the company's bylaws. In fairness to all stockholders attending the reconvened meeting, in the interest of an orderly meeting when stockholders or their authorized proxies are provided an opportunity to speak or ask questions during the meeting, we ask that you follow the rules of conduct, a copy of which was provided to you when you accessed the virtual meeting room. As previously mentioned, Proposal One and Proposal Two are being considered at this reconvened special meeting since there were not sufficient votes to approve either proposal. Based upon the additional proxies received prior to the start of this reconvened meeting, there continues to be an insufficient number of votes to approve Proposal One and Proposal Two. Therefore, NovaBay will be adjourning the meeting for Proposal One and Proposal Two in order to continue soliciting additional votes in favor of increasing the number of shares voted. At this time, we would like to entertain questions or comments from our stockholders. We'd appreciate you identifying yourself by name and organization as a stockholder. Please feel free to address your questions specifically to any of the officers or directors who are present. Does not look like we have any questions, so this will conclude the question-and-answer session. With the approval by stockholders at the special meeting of the proposal authorizing the adjournment of the special meeting, and given that NovaBay did not receive enough votes from stockholders of record to approve Proposal One for the sale of Avenova or Proposal Two to approve the liquidation and dissolution of NovaBay, NovaBay is hereby adjourning this meeting as to those two proposals in order to solicit additional votes in favor of approving both such proposals. I now declare that this meeting be adjourned and that the special meeting will be reconvened at 11:00 A.M. Pacific Time on January 16th, 2025, at the same virtual meeting website as today's meeting and as provided in the proxy statement. All stockholders of record, as of October 15th, 2024, which is the record date for this meeting, will continue to be entitled to vote at the reconvened special meeting. This concludes our business for today. Thank you for attending today and for your continued interest in NovaBay Pharmaceuticals, and we look forward to seeing you on January 16th, 2025, at the reconvened meeting. That concludes today's meeting. Thank you for joining, and have a pleasant day.